Cell Surface Marker Expression in Autoimmune Diseases

A Cross-Sectional Study of Cell Surface Marker Expression in Participants With Autoimmune or Inflammatory Diseases

NCT03757065•Alpine Immune Sciences, Inc.

Summary

This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's disease, (f) ulcerative colitis and (g) inflammatory myositis.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female participants 19 years of age or older.
•2. Participant or legal surrogate able and willing to provide written, informed consent.
•3. Participant is, or has been undergoing care for one of the specified diseases in a participating centre with a confirmed clinical diagnosis of the specified disease.
•4. Participant has or will provide the relevant peripheral blood (required) and normal practice tissue specimens (if available).
•5. Participant has one of the following target auto-immune or inflammatory diseases diagnosed according to local clinical practice guidelines:
•1. Crohn's Disease
•2. Inflammatory myositis
•3. Multiple sclerosis
•4. Sjogren's syndrome
•5. Systemic lupus erythematosus
+2 more criteria

Exclusion Criteria

•1. Participants receiving investigational therapy within 30 days or 5 half-lives, whichever is longer, prior to enrolment.
•2. Participants suffering from any additional disease that may interfere with the biomarker signals as per the investigator's discretion.

Locations (2)

GI Research Institute

Vancouver, British Columbia, Canada

Mary Pack Arthritis Center

Vancouver, Canada

Key Dates

Start Date

June 12, 2019

Primary Completion Date

October 25, 2019

Completion Date

October 25, 2019

Last Updated

August 27, 2020

Enrollment

ACTUAL participants

Conditions

Systemic Lupus ErythematosusSjogren's SyndromeMultiple SclerosisSystemic SclerosisCrohn's DiseaseUlcerative ColitisInflammatory Myositis

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

RECRUITINGPHASE1

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT06647069

Systemic Lupus Erythematosus (SLE)Rheumatoid Arthritis (RA)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 27, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cell Surface Marker Expression in Autoimmune Diseases

Inclusion Criteria

Exclusion Criteria

Intermittent Hypoxia in Persons With Multiple Sclerosis

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy